VEGFA and ulcerative colitis: Bevacizumab, a monoclonal antibody directed against VEGF-A, has demonstrated encouraging results in mitigating inflammation and inducing remission in patients with ulcerative colitis (UC) and Crohn’s disease (CD) [111,112,113].